Cancer and Immunotherapy · global
Personalized mRNA cancer vaccine meets phase 3 endpoints, adding evidence for postsurgical melanoma treatment
A vaccine tailored to each patient’s tumor mutations, combined with Keytruda, improved recurrence-free and distant metastasis-free survival in a large trial. However, the August announcement did not disclose the magnitude of benefit, and whether it extends life remains under follow-up.
Surgery removes melanoma, but the risk of recurrence does not necessarily disappear with it. Helping the immune system continue to recognize cancer cells after surgery is an important challenge in adjuvant treatment. On August 19, 2026, Merck and Moderna announced that the personalized mRNA therapy intismeran autogene, combined with the immunotherapy drug Keytruda, met two key efficacy endpoints in a phase 3 trial, providing large-scale clinical evidence for this treatment approach.
The global trial, called INTerpath-001, enrolled 1,137 patients with completely resected stage IIB to IV cutaneous melanoma. Patients were randomized in a two-to-one ratio to compare the combination with Keytruda alone. The companies said a prespecified interim analysis showed statistically significant improvements in both recurrence-free survival and distant metastasis-free survival in the combination group. Here, “phase 3” refers to the stage of clinical development; participants received adjuvant treatment after surgery.
Intismeran autogene, also known as V940 or mRNA-4157, is designed using each patient’s own tumor as its starting point. Researchers identify neoantigens produced by tumor mutations, then encode the corresponding protein-making instructions in mRNA, with the aim of guiding the immune system to recognize cancer cells bearing these features. It is a therapeutic vaccine intended to help fight cancer that has already developed, rather than a vaccine for the general population to prevent cancer.
Keytruda, the drug paired with it, has the generic name pembrolizumab and is an immune checkpoint inhibitor that blocks PD-1. The rationale for combining the two is to provide clues for recognizing the tumor while also relieving some of the suppression of the immune response. This trial tested the added benefit of a personalized vaccine on top of existing immunotherapy, so the results cannot be interpreted as proof that the vaccine is also effective on its own.
Merck and Moderna described these results as the first positive phase 3 results for a personalized neoantigen therapy and an mRNA cancer therapy. Reports published the same day by C&EN and STAT also described this as an important advance in cancer vaccines, but the two companies had not released detailed data at the time. The announcement was insufficient to answer how much the risk of recurrence was reduced, whether patients at different stages benefited consistently, or how many people would need to be treated to prevent one recurrence.
On safety, the companies said no new safety signals were observed and the overall profile was consistent with earlier studies; however, this does not mean there were no side effects. Without complete data on adverse events, their severity, and treatment discontinuations, it remains difficult to assess the treatment burden accompanying the added efficacy. The recurrence-free survival endpoint also includes deaths and cannot directly substitute for overall survival results; the trial will continue to follow patients to determine whether they live longer.
According to the August announcement, the two companies planned to present detailed results at an international medical meeting and discuss regulatory submissions with regulators. These findings bring personalized cancer vaccines a step closer to clinical use, but meeting trial endpoints and obtaining approval remain different stages. The full data will determine how much this success, announced in an early disclosure, can change postsurgical care for melanoma.